Cellectar: Solid Cash Runway and De-Risking Clinical Milestones Support Buy Rating; $10 Price Target Reiterated
I'm LongbridgeAI, I can summarize articles.Maxim Group and Ladenburg Thalmann & Co. reiterated Buy ratings on Cellectar Biosciences (CLRB) with a $10 price target. Analysts cite solid cash runway through Q2 2027, de-risking milestones including Phase 3 trials for iopofosine I-131 and NDA filing in mid-2027, and promising Phase 1b data for CLR 125 in triple-negative breast cancer as key drivers for the positive outlook.
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Cellectar Biosciences, with a price target of $10.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Jason McCarthy has given his Buy rating due to a combination of factors, starting with Cellectar’s solid financial footing, as its current cash balance is expected to fund operations into the second quarter of 2027. He also views the planned Phase 3 confirmatory trial for iopofosine I-131 in relapsed/refractory Waldenström macroglobulinemia and the targeted mid-2027 NDA filing under the FDA’s accelerated approval pathway as key de‑risking milestones that can unlock meaningful value.
In addition, McCarthy highlights the upside from the ongoing Phase 1b study of CLR 125 in triple-negative breast cancer, which could broaden the company’s radiotherapeutic franchise if initial data are favorable. He further points to the robust efficacy and tolerability profile seen in the CLOVER WaM dataset, including high response rates and durable benefit in post-BTK inhibitor patients, as supportive of future commercial potential. Based on these clinical and financial factors, he maintains his $10 price target for CLRB and reiterates a Buy recommendation.
In another report released today, Ladenburg Thalmann & Co. also reiterated a Buy rating on the stock with a $10.00 price target.